Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib and Dostarlimab in recurrent ovarian cancer (NItCHE)
NCT04679064Phase 3
Key facts
- Status
- Unknown
- Start
- Dec 2020
- Primary completion
- Jan 2025
- Countries
- 1
- Sponsor
- Policlinico Gemelli
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Drugs
- niraparibdostarlimab
- Conditions
- ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
01
Overview
Phase 3, randomised, open-label trial of niraparib and dostarlimab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Policlinico Gemelli. Status: unknown.
02
Design
- Study design
- RandomizedOpen-label
03
Registry description
Randomized phase 3 trial evaluating niraparib plus dostarlimab vs chemotherapy at physician's choice in the treatment of recurrent ovarian, fallopian tube or primary peritoneal cancer patients for which platinum is not an option
Beyond the preview
Go deeper on NCT04679064.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04679064.